{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T15:08:54Z","timestamp":1764601734827},"reference-count":31,"publisher":"Japanese Circulation Society","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Circ J"],"published-print":{"date-parts":[[2020,9,25]]},"DOI":"10.1253\/circj.cj-20-0060","type":"journal-article","created":{"date-parts":[[2020,8,27]],"date-time":"2020-08-27T22:11:59Z","timestamp":1598566319000},"page":"1837-1845","source":"Crossref","is-referenced-by-count":6,"title":["Increased Serum Malondialdehyde-Modified Low-Density Lipoprotein and Coronary Angiographic Progression After Drug-Eluting Stent Implantation in Patients With Stable Angina"],"prefix":"10.1253","volume":"84","author":[{"given":"Masashi","family":"Yokoi","sequence":"first","affiliation":[{"name":"Department of Cardiology, Nagoya City University Graduate School of Medical Sciences"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tsuyoshi","family":"Ito","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Nagoya City University Graduate School of Medical Sciences"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Fujita","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Nagoya City University Graduate School of Medical Sciences"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomonori","family":"Sugiura","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Nagoya City University Graduate School of Medical Sciences"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshihiro","family":"Seo","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Nagoya City University Graduate School of Medical Sciences"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobuyuki","family":"Ohte","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Nagoya City University Graduate School of Medical Sciences"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"330","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Piccolo R, Bonaa KH, Efthimiou O, Varenne O, Baldo A, Urban P, et al. Drug-eluting or bare-metal stents for percutaneous coronary intervention: A systematic review and individual patient data meta-analysis of randomised clinical trials. <i>Lancet<\/i> 2019; 393: 2503\u20132510.","DOI":"10.1016\/S0140-6736(19)30474-X"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. B\u00f8naa KH, Mannsverk J, Wiseth R, Aaberge L, Myreng Y, Nyg\u00e5rd O, et al. Drug-eluting or bare-metal stents for coronary artery disease. <i>N Engl J Med<\/i> 2016; 375: 1242\u20131252.","DOI":"10.1056\/NEJMoa1607991"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Taguchi I, Iimuro S, Iwata H, Takashima H, Abe M, Amiya E, et al. High-dose versus low-dose pitavastatin in Japanese patients with stable coronary artery disease (REAL-CAD) a randomized superiority trial. <i>Circulation<\/i> 2018; 137: 1997\u20132009.","DOI":"10.1161\/CIRCULATIONAHA.117.032615"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Cannon CP, Blazing MA, Giugliano RP, McCagg A, White JA, Theroux P, et al. Ezetimibe added to statin therapy after acute coronary syndromes. <i>N Engl J Med<\/i> 2015; 372: 2387\u20132397.","DOI":"10.1056\/NEJMoa1410489"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Stone GW, Maehara A, Lansky AJ, de Bruyne B, Cristea E, Mintz GS, et al. A prospective natural-history study of coronary atherosclerosis. <i>N Engl J Med<\/i> 2011; 364: 226\u2013235.","DOI":"10.1056\/NEJMoa1002358"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Waters D, Craven TE, Lesperance J. Prognostic significance of progression of coronary atherosclerosis. <i>Circulation<\/i> 1993; 87: 1067\u20131075.","DOI":"10.1161\/01.CIR.87.4.1067"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Kaski JC, Chester MR, Chen L, Katritsis D. Rapid angiographic progression of coronary artery disease in patients with angina pectoris. <i>Circulation<\/i> 1995; 92: 2058\u20132065.","DOI":"10.1161\/01.CIR.92.8.2058"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Zouridakis E, Avanzas P, Arroyo-Espliguero R, Fredericks S, Kaski JC. Markers of inflammation and rapid coronary artery disease progression in patients with stable angina pectoris. <i>Circulation<\/i> 2004; 110: 1747\u20131753.","DOI":"10.1161\/01.CIR.0000142664.18739.92"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Puri R, Ballantyne CM, Hoogeveen RC, Shao M, Barter P, Libby P, et al. Lipoprotein(a) and coronary atheroma progression rates during long-term high-intensity statin therapy: Insights from SATURN. <i>Atherosclerosis<\/i> 2017; 263: 137\u2013144.","DOI":"10.1016\/j.atherosclerosis.2017.06.026"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Bor\u00e9n J, Chapman MJ, Krauss RM, Packard CJ, Bentzon JF, Binder CJ, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease: Pathophysiological, genetic, and therapeutic insights: A consensus statement from the European Atherosclerosis Society Consensus Panel. <i>Eur Heart J<\/i> 2020; 41: 2313\u20132330.","DOI":"10.1093\/eurheartj\/ehz962"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Amaki T, Suzuki T, Nakamura F, Hayashi D, Imai Y, Morita H, et al. Circulating malondialdehyde modified LDL is a biochemical risk marker for coronary artery disease. <i>Heart<\/i> 2004; 90: 1211\u20131213.","DOI":"10.1136\/hrt.2003.018226"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Matsuo Y, Kubo T, Okumoto Y, Ishibashi K, Komukai K, Tanimoto T, et al. Circulating malondialdehyde-modified low-density lipoprotein levels are associated with the presence of thin-cap fibroatheromas determined by optical coherence tomography in coronary artery disease. <i>Eur Heart J Cardiovasc Imaging<\/i> 2013; 14: 43\u201350.","DOI":"10.1093\/ehjci\/jes094"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Holvoet P, Collen D, Van De Werf F. Malondialdehyde-modified LDL as a marker of acute coronary syndromes. <i>J Am Med Assoc<\/i> 1999; 281: 1718\u20131721.","DOI":"10.1001\/jama.281.18.1718"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Ito T, Fujita H, Tani T, Ohte N. Malondialdehyde-modified low-density lipoprotein is a predictor of cardiac events in patients with stable angina on lipid-lowering therapy after percutaneous coronary intervention using drug-eluting stent. <i>Atherosclerosis<\/i> 2015; 239: 311\u2013317.","DOI":"10.1016\/j.atherosclerosis.2015.01.026"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Kotani K, Maekawa M, Kanno T, Kondo A, Toda N, Manabe M. Distribution of immunoreactive malondialdehyde-modified low-density lipoprotein in human serum. <i>Biochim Biophys Acta (BBA)\/Lipids Lipid Metab<\/i> 1994; 1215: 121\u2013125.","DOI":"10.1016\/0005-2760(94)90100-7"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Sugiuchi H, Irie T, Uji Y, Ueno T, Chaen T, Uekama K, et al. Homogeneous assay for measuring low-density lipoprotein cholesterol in serum with triblock copolymer and \u03b1-cyclodextrin sulfate. <i>Clin Chem<\/i> 1998; 44: 522\u2013531.","DOI":"10.1093\/clinchem\/44.3.522"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Teramoto T, Sasaki J, Ishibashi S, Birou S, Daida H, Dohi S, et al. Diagnosis of atherosclerosis: Executive summary of the Japan Atherosclerosis Society (JAS) guidelines for the diagnosis and prevention of atherosclerotic cardiovascular diseases in Japan - 2012 version. <i>J Atheroscler Thromb<\/i> 2014; 21: 296\u2013298.","DOI":"10.5551\/jat.19737"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Stone GW, Pieter Kappetein A, Sabik JF, Pocock SJ, Morice MC, Puskas J, et al. Five-year outcomes after PCI or CABG for left main coronary disease. <i>N Engl J Med<\/i> 2019; 381: 1820\u20131830.","DOI":"10.1056\/NEJMoa1909406"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Nakazawa G, Otsuka F, Nakano M, Vorpahl M, Yazdani SK, Ladich E, et al. The pathology of neoatherosclerosis in human coronary implants bare-metal and drug-eluting stents. <i>J Am Coll Cardiol<\/i> 2011; 57: 1314\u20131322.","DOI":"10.1016\/j.jacc.2011.01.011"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Boden WE, O\u2019Rourke RA, Teo KK, Hartigan PM, Maron DJ, Kostuk WJ, et al. Optimal medical therapy with or without PCI for stable coronary disease. <i>N Engl J Med<\/i> 2007; 356: 1503\u20131516.","DOI":"10.1056\/NEJMoa070829"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Lautam\u00e4ki A, Airaksinen KEJ, Kiviniemi T, Vinco G, Ribichini F, Gunn J, et al. Prognosis and disease progression in patients under 50 years old undergoing PCI: The CRAGS (Coronary aRtery diseAse in younG adultS) study. <i>Atherosclerosis<\/i> 2014; 235: 483\u2013487.","DOI":"10.1016\/j.atherosclerosis.2014.05.953"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Madamanchi NR, Vendrov A, Runge MS. Oxidative stress and vascular disease. <i>Arterioscler Thromb Vasc Biol<\/i> 2005; 25: 29\u201338.","DOI":"10.1161\/01.ATV.0000150649.39934.13"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Ley K, Miller YI, Hedrick CC. Monocyte and macrophage dynamics during atherogenesis. <i>Arterioscler Thromb Vasc Biol<\/i> 2011; 31: 1506\u20131516.","DOI":"10.1161\/ATVBAHA.110.221127"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Tsujita K, Sugiyama S, Sumida H, Shimomura H, Yamashita T, Yamanaga K, et al. Impact of dual lipid-lowering strategy with ezetimibe and atorvastatin on coronary plaque regression in patients with percutaneous coronary intervention: The Multicenter Randomized Controlled PRECISE-IVUS Trial. <i>J Am Coll Cardiol<\/i> 2015; 66: 495\u2013507.","DOI":"10.1016\/j.jacc.2015.05.065"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Knuuti J, Wijns W, Saraste A, Capodanno D, Barbato E, Funck-Brentano C, et al. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. <i>Eur Heart J<\/i> 2020; 41: 407\u2013477.","DOI":"10.1093\/eurheartj\/ehz425"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Bayturan O, Kapadia S, Nicholls SJ, Tuzcu EM, Shao M, Uno K, et al. Clinical predictors of plaque progression despite very low levels of low-density lipoprotein cholesterol. <i>J Am Coll Cardiol<\/i> 2010; 55: 2736\u20132742.","DOI":"10.1016\/j.jacc.2010.01.050"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Krauss RM, Burke DJ. Identification of multiple subclasses of plasma low density lipoproteins in normal humans. <i>J Lipid Res<\/i> 1982; 23: 97\u2013104.","DOI":"10.1016\/S0022-2275(20)38178-5"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Hoogeveen RC, Gaubatz JW, Sun W, Dodge RC, Crosby JR, Jiang J, et al. Small dense low-density lipoprotein-cholesterol concentrations predict risk for coronary heart disease: The Atherosclerosis Risk In Communities (ARIC) study. <i>Arterioscler Thromb Vasc Biol<\/i> 2014; 34: 1069\u20131077.","DOI":"10.1161\/ATVBAHA.114.303284"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29. Mikhailidis DP, Elisaf M, Rizzo M, Berneis K, Griffin B, Zambon A, et al. \u201cEuropean panel on low density lipoprotein (LDL) subclasses\u201d: A statement on the pathophysiology, atherogenicity and clinical significance of LDL subclasses. <i>Curr Vasc Pharmacol<\/i> 2011; 9: 533\u2013571.","DOI":"10.2174\/157016111796642661"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30. Gazi I, Tsimihodimos V, Filippatos T, Bairaktari E, Tselepis AD, Elisaf M. Concentration and relative distribution of low-density lipoprotein subfractions in patients with metabolic syndrome defined according to the National Cholesterol Education Program criteria. <i>Metabolism<\/i> 2006; 55: 885\u2013891.","DOI":"10.1016\/j.metabol.2006.02.015"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31. Guedeney P, Claessen BE, Kalkman DN, Aquino M, Sorrentino S, Giustino G, et al. Residual inflammatory risk in patients with low LDL cholesterol levels undergoing percutaneous coronary intervention. <i>J Am Coll Cardiol<\/i> 2019; 73: 2401\u20132409.","DOI":"10.1016\/j.jacc.2019.01.077"}],"container-title":["Circulation Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/circj\/84\/10\/84_CJ-20-0060\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,29]],"date-time":"2021-03-29T17:36:25Z","timestamp":1617039385000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/circj\/84\/10\/84_CJ-20-0060\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,25]]},"references-count":31,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1253\/circj.cj-20-0060","relation":{},"ISSN":["1346-9843","1347-4820"],"issn-type":[{"value":"1346-9843","type":"print"},{"value":"1347-4820","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,25]]}}}